Courtney L Walker, Chelsea N Shope, Laura A Andrews, Kelly M Atherton, Tyler Beck, Gabriella Santa Lucia, Gregory Fridman, Peter C Friedman, Colleen H Cotton, Lara Wine Lee
{"title":"分析非热大气等离子体治疗小儿疣的随机对照试验","authors":"Courtney L Walker, Chelsea N Shope, Laura A Andrews, Kelly M Atherton, Tyler Beck, Gabriella Santa Lucia, Gregory Fridman, Peter C Friedman, Colleen H Cotton, Lara Wine Lee","doi":"10.1016/j.jaad.2024.07.1522","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Verruca vulgaris (VV) is a common viral disease in children. Treatment options are often not well tolerated in children due to pain or adverse effect risk. Nonthermal atmospheric plasma (NTAP), which generates reactive oxygen/nitrogen species, is well tolerated and without adverse effects.</p><p><strong>Objective: </strong>Determine efficacy of NTAP as compared to standard of care (SOC) therapy for VV in children.</p><p><strong>Methods: </strong>This prospective open-label study randomized lesions 1:1 to receive NTAP or SOC (cryotherapy). Patients were treated at 4-week intervals for a maximum of 3 treatments. They were evaluated 4 weeks postfinal treatment for sustained response. Primary outcome was lesion response.</p><p><strong>Results: </strong>One hundred twelve VV lesions in 14 patients were enrolled. Patients were mostly White (92.9%) males (71.4%) with mean age of 9.5 [±2.5] years. Responses of SOC- and NTAP-treated lesions, respectively, included no response (5.4%, 7.1%); partial response (33.9%, 41.1%); and complete resolution (60.7%, 51.8%; P value = .679). Patients were more likely to report pain in SOC lesions post-treatment (P value <.001). No significant adverse events (AEs) occurred.</p><p><strong>Limitations: </strong>Limitations include single-site, maximum of 3 treatments, and short post-treatment follow-up.</p><p><strong>Conclusion: </strong>NTAP is an efficacious, safe intervention for treatment of VV in children.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":"46-50"},"PeriodicalIF":12.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A randomized controlled trial analyzing nonthermal atmospheric plasma for the treatment of verruca vulgaris in pediatric patients.\",\"authors\":\"Courtney L Walker, Chelsea N Shope, Laura A Andrews, Kelly M Atherton, Tyler Beck, Gabriella Santa Lucia, Gregory Fridman, Peter C Friedman, Colleen H Cotton, Lara Wine Lee\",\"doi\":\"10.1016/j.jaad.2024.07.1522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Verruca vulgaris (VV) is a common viral disease in children. Treatment options are often not well tolerated in children due to pain or adverse effect risk. Nonthermal atmospheric plasma (NTAP), which generates reactive oxygen/nitrogen species, is well tolerated and without adverse effects.</p><p><strong>Objective: </strong>Determine efficacy of NTAP as compared to standard of care (SOC) therapy for VV in children.</p><p><strong>Methods: </strong>This prospective open-label study randomized lesions 1:1 to receive NTAP or SOC (cryotherapy). Patients were treated at 4-week intervals for a maximum of 3 treatments. They were evaluated 4 weeks postfinal treatment for sustained response. Primary outcome was lesion response.</p><p><strong>Results: </strong>One hundred twelve VV lesions in 14 patients were enrolled. Patients were mostly White (92.9%) males (71.4%) with mean age of 9.5 [±2.5] years. Responses of SOC- and NTAP-treated lesions, respectively, included no response (5.4%, 7.1%); partial response (33.9%, 41.1%); and complete resolution (60.7%, 51.8%; P value = .679). Patients were more likely to report pain in SOC lesions post-treatment (P value <.001). No significant adverse events (AEs) occurred.</p><p><strong>Limitations: </strong>Limitations include single-site, maximum of 3 treatments, and short post-treatment follow-up.</p><p><strong>Conclusion: </strong>NTAP is an efficacious, safe intervention for treatment of VV in children.</p>\",\"PeriodicalId\":17198,\"journal\":{\"name\":\"Journal of the American Academy of Dermatology\",\"volume\":\" \",\"pages\":\"46-50\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Academy of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jaad.2024.07.1522\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Academy of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaad.2024.07.1522","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
A randomized controlled trial analyzing nonthermal atmospheric plasma for the treatment of verruca vulgaris in pediatric patients.
Background: Verruca vulgaris (VV) is a common viral disease in children. Treatment options are often not well tolerated in children due to pain or adverse effect risk. Nonthermal atmospheric plasma (NTAP), which generates reactive oxygen/nitrogen species, is well tolerated and without adverse effects.
Objective: Determine efficacy of NTAP as compared to standard of care (SOC) therapy for VV in children.
Methods: This prospective open-label study randomized lesions 1:1 to receive NTAP or SOC (cryotherapy). Patients were treated at 4-week intervals for a maximum of 3 treatments. They were evaluated 4 weeks postfinal treatment for sustained response. Primary outcome was lesion response.
Results: One hundred twelve VV lesions in 14 patients were enrolled. Patients were mostly White (92.9%) males (71.4%) with mean age of 9.5 [±2.5] years. Responses of SOC- and NTAP-treated lesions, respectively, included no response (5.4%, 7.1%); partial response (33.9%, 41.1%); and complete resolution (60.7%, 51.8%; P value = .679). Patients were more likely to report pain in SOC lesions post-treatment (P value <.001). No significant adverse events (AEs) occurred.
Limitations: Limitations include single-site, maximum of 3 treatments, and short post-treatment follow-up.
Conclusion: NTAP is an efficacious, safe intervention for treatment of VV in children.
期刊介绍：
The Journal of the American Academy of Dermatology (JAAD) is the official scientific publication of the American Academy of Dermatology (AAD). Its primary goal is to cater to the educational requirements of the dermatology community. Being the top journal in the field, JAAD publishes original articles that have undergone peer review. These articles primarily focus on clinical, investigative, and population-based studies related to dermatology. Another key area of emphasis is research on healthcare delivery and quality of care. JAAD also highlights high-quality, cost-effective, and innovative treatments within the field. In addition to this, the journal covers new diagnostic techniques and various other topics relevant to the prevention, diagnosis, and treatment of skin, hair, and nail disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
